Genomics

Dataset Information

0

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma


ABSTRACT: We examined pre-treatment tumors from participants of the IMmotion150 trial. Biomarker analyses indicate that high angiogenesis gene expression was associated with improved PFS within the sunitinib arm, and high T-effector/IFNγ response (Teff) gene expression with longer PFS in atezolizumab + bevacizumab vs sunitinib patients. In high Teff tumors, concomitant high myeloid inflammation was associated with worse PFS in the atezolizumab monotherapy arm; adding bevacizumab to atezolizumab in this subgroup improved PFS vs atezolizumab. Molecular profiles suggest that prediction of outcomes with VEGF inhibitors and immunotherapy may be possible in mRCC, and bevacizumab may overcome myeloid inflammation-associated atezolizumab resistance.

PROVIDER: EGAS00001002928 | EGA |

REPOSITORIES: EGA

Similar Datasets

2016-07-06 | E-GEOD-84010 | biostudies-arrayexpress
2011-01-07 | E-GEOD-25698 | biostudies-arrayexpress
2024-08-26 | GSE275628 | GEO
2014-11-14 | E-GEOD-36864 | biostudies-arrayexpress
2013-12-18 | E-GEOD-53127 | biostudies-arrayexpress
2016-07-06 | GSE84010 | GEO
2013-12-18 | GSE53127 | GEO
| EGAS00001005503 | EGA
2011-01-07 | GSE25698 | GEO
2018-11-21 | GSE110785 | GEO